PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

Bovaclox* DC LA

DRY COW INTRAMAMMARY SUSPENSION

PRESENTATION
BOVACLOX DC LA is a stable intramammary suspension prepared under sterile conditions. Each 5.4 g syringe contains 600 mg cloxacillin (as benzathine salt) and 300 mg ampicillin (as trihydrate) in a long-acting base.

USES
BOVACLOX DC LA is formulated for the control of mastitis at the point of drying off i.e., immediately after the last milking of the lactation. Effective antibiotic levels are maintained in the udder of the dry cow for up to 10 weeks. BOVACLOX DC LA is bactericidal in action and is non-irritant in the udder tissues.

BOVACLOX DC LA is highly effective against *Streptococcus agalactiae* and other streptococcal species, penicillin resistant and sensitive *Staphylococcus* spp and *Arcanobacterium pyogenes* and other species susceptible to cloxacillin.

DIRECTIONS FOR USE
Restraints:
DO NOT USE in lactating cows or within 49 days of calving.

Precautions:
If BOVACLOX DC LA is accidentally administered to a lactating animal or within 49 days of calving, contact the prescribing veterinarian for advice.

Avoid use in cows that are allergic to penicillin.

Rubber gloves should be worn when infusing the suspension.

Infuse the contents of one syringe into each quarter after the final milking before drying off. The cow should be milked out normally and the teats cleaned and disinfected before infusion with the antibiotic.
BOVACLOX DC LA is presented in syringes with a **variable tip.** This variable tip allows for either full or partial insertion into the teat orifice. Partial insertion only is preferable, as it may prevent unnecessary damage to the teat orifice. Full insertion will be needed for large teat orifices.

There is evidence that partial insertion can reduce the incidence of *Staphylococcus aureus* and *Streptococcus uberis* infections (Boddie et al, 1990).

Standard Syringe Tip

Variable Syringe Tip

Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route, disease or target species may require extending the approved withholding period.

WITHHOLDING PERIODS
MILK: DO NOT USE in lactating cows or within 49 days of calving. After calving, colostrum or milk from treated dry cows MUST NOT BE USED for human consumption or processing for 96 hours (8 milkings). If premature or unscheduled calving occurs, consult the prescribing veterinarian for advice on handling milk for bobby calves.

MEAT: DO NOT USE less than 30 days before slaughter for human consumption.

TRADE ADVICE:EXPORT SLAUGHTER INTERVAL (ESI): This product does not have an ESI established. For advice on the ESI, contact the manufacturer on 1800 665 866 before using this product.

FIRST AID
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Manufactured by:
Norbrook Laboratories Limited, United Kingdom

Distributed by:
Norbrook Laboratories Australia Pty Limited
ACN 080 972 596
Unit 7/15- 21 Butler Way, Tullamarine, VIC 3043

Free call: 1800 665 866

DISPOSAL
Dispose of empty container by wrapping with paper and putting in garbage.

STORAGE
Store below 25°C (Air Conditioning). Protect from light.

APVMA Approval No.: 51078/0909

PRESENTATION
BOVACLOX DC LA is packaged in individual dose 5.4 g intramammary syringes and is available in cartons of 20 syringes and buckets of 200 syringes.

027411I03

Norbrook®